Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

When Is an ICD Considered After a Heart Attack with Low EF?

At a Glance

After a heart attack, doctors usually wait at least 40 days—and often about 90 days after stents or bypass—to recheck ejection fraction and optimize medicines. An ICD is generally considered if ejection fraction stays at 35% or lower and overall health supports the procedure.

If your ejection fraction is low right after a heart attack, an implantable cardioverter-defibrillator (ICD) is usually not placed immediately. Instead, guidelines require a waiting period: at least 40 days after the heart attack, and doctors commonly wait to reassess your heart about 90 days after any revascularization procedures (like stents or bypass surgery) [1][2].

During this time, your medical team will focus on maximizing your heart failure medications to give your heart muscle a chance to recover [3]. After this waiting period, your doctor will check your heart’s pumping ability again. An ICD is generally only considered for primary prevention if your ejection fraction remains at 35% or lower, you are on the highest tolerated doses of medications, and you have a reasonable expectation of meaningful survival for more than one year [4][5].

Understanding Ejection Fraction and Heart Recovery

An ejection fraction (EF) is the percentage of blood your heart pumps out of its main chamber with each contraction. A normal EF is usually between 50% and 70%. When you have an acute myocardial infarction (heart attack), the lack of blood flow damages the heart muscle, often causing the EF to drop.

While muscle destroyed by the heart attack can become permanent scar tissue, other areas of the heart may experience myocardial stunning. This means the muscle is viable but temporarily weakened by the event [2]. Over weeks or months, as blood flow is restored and medications take effect, this stunned muscle can recover its function. This improvement in the heart’s size, shape, and pumping ability is called reverse remodeling [2][6]. Because of this potential for recovery, an initially low EF does not guarantee it will stay low forever.

It is natural to feel anxious about waiting for a protective device. However, clinical trials have shown that routinely placing an ICD immediately after a heart attack does not improve overall survival [1]. While an early ICD can prevent sudden arrhythmic death, patients in the early recovery period still face other non-arrhythmic risks that an ICD cannot fix [7]. Waiting allows doctors to identify which patients actually need a permanent device and which patients recover enough function that an ICD is no longer necessary [2].

Note: An ICD is designed to detect and treat life-threatening heart rhythms. It does not open blocked arteries, cure heart failure, or replace the need for medications and lifestyle changes.

Optimizing Your Medications

A major part of the waiting period involves starting and adjusting your heart medications, known as guideline-directed medical therapy (GDMT). These medications reduce harmful remodeling, improve long-term outcomes, and can sometimes help improve your EF [3].

For a low EF, doctors aim to prescribe four foundational classes of medication:

  • Beta-blockers
  • ACE inhibitors, ARBs, or ARNIs (like Entresto)
  • Mineralocorticoid-receptor antagonists (MRAs)
  • SGLT2 inhibitors

The goal is to reach the maximally tolerated dose for you [8]. Not everyone can reach the highest “target” doses because these drugs can affect your blood pressure, heart rate, kidney function, and potassium levels [9][10]. Your doctor will individualize your doses and monitor your bloodwork closely. In addition to these four classes, you will likely also be on antiplatelet medications and statins to prevent another heart attack [11].

Primary vs. Secondary Prevention

When deciding if you need an ICD, doctors use two different pathways:

  • Primary Prevention: This means placing an ICD to prevent a future life-threatening heart rhythm before one has ever happened. The 40-day (post-MI) to 90-day (post-revascularization) waiting periods apply to primary prevention, giving your heart time to respond to medications [4][12]. For primary prevention, doctors consider your EF (often ≤35%, though sometimes ≤30% depending on your symptom level), your functional status, and your overall health [13].
  • Secondary Prevention: This applies if you have survived a cardiac arrest or documented dangerous rhythms, such as sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). In these cases, an ICD is considered promptly after stabilization [14][15]. However, there is an important exception: If VT or VF happens during the first 24 to 48 hours of a heart attack, it is often caused by temporary, reversible ischemia (lack of blood flow). Once the blocked artery is opened and the ischemia is treated, a permanent ICD may not be required [16].

Monitoring and Wearable Defibrillators

While waiting for your heart to heal, your doctor may use monitors (like a Holter monitor or chest patch) to watch for abnormal heartbeats, such as non-sustained ventricular tachycardia (NSVT) [17]. NSVT is a brief run of fast heartbeats that stops on its own. While it provides useful risk information to your doctor, having NSVT does not automatically mean sudden death is imminent or that you immediately need an ICD.

Your doctor might also discuss a wearable cardioverter-defibrillator (WCD), often known by the brand name LifeVest. This is a garment worn under your clothes that monitors your heart and can deliver a shock if a life-threatening rhythm occurs [18][19].

  • A WCD is not prescribed routinely to everyone after a heart attack, as definitive evidence proving a survival benefit for all post-MI patients is mixed [1][20].
  • It is a selective “bridge” therapy considered on a case-by-case basis [18].
  • If prescribed, it must be worn almost continuously (except for bathing) to provide protection [1]. Your care team will teach you how to manage the battery, skin care, and what to do if the device sounds an alarm.

Electrophysiology Consultation

If your EF remains borderline, or if monitors detect specific abnormal rhythms, your cardiologist might refer you to an electrophysiologist (EP)—a cardiologist who specializes in the heart’s electrical system.

An EP consultation does not automatically mean you need surgery. While they may recommend an invasive electrophysiology (EP) study to test your heart’s electrical pathways, this test is selective and not routinely required for all patients with a low EF [21]. The EP specialist will help decide if you need an ICD, or perhaps a specialized device called a CRT-D (cardiac resynchronization therapy defibrillator), based on your specific electrical conduction patterns.


🚨 When to Call Emergency Services (911)

Do not wait for a routine doctor’s appointment if you experience signs of a medical emergency. Call 911 immediately if you have:

  • Sudden, severe chest pain, pressure, or tightness
  • Severe or worsening shortness of breath
  • Fainting, passing out, or sudden collapse
  • A sustained, rapid, or violently racing heartbeat that does not stop
  • If your wearable cardioverter-defibrillator (WCD) delivers a shock

Common questions in this guide

How long after a heart attack do doctors wait before considering an ICD?
For primary prevention, an ICD is usually not implanted immediately after a heart attack. Doctors generally wait at least 40 days after the heart attack and often reassess the ejection fraction about 90 days after stents or bypass surgery while heart-failure medicines are optimized. If the ejection fraction remains low, the care team then evaluates whether an ICD is appropriate.
What ejection fraction usually leads to an ICD after a heart attack?
After the waiting period and treatment with the highest dose of heart-failure medicine you can safely tolerate, an ICD for primary prevention is generally considered when the ejection fraction remains 35% or lower. In some situations, a cutoff of 30% is used based on symptoms and other factors. Overall health, functional status, rhythm history, and expected survival also matter.
Why is an ICD not placed right away when ejection fraction is low after a heart attack?
A low ejection fraction soon after a heart attack may improve because some heart muscle is temporarily stunned rather than permanently damaged. Restored blood flow and optimized medicines can allow the heart to recover over weeks or months. Trials have not shown that routine early ICD placement improves overall survival.
Does a dangerous heart rhythm mean I need an ICD immediately?
A cardiac arrest or sustained ventricular tachycardia or ventricular fibrillation after stabilization can lead to prompt consideration of an ICD for secondary prevention. However, these rhythms during the first 24 to 48 hours of a heart attack may be caused by temporary loss of blood flow and may not require a permanent ICD after the cause is treated. The decision depends on the rhythm, timing, and recovery.
Could I use a LifeVest while waiting for an ICD decision?
A wearable cardioverter-defibrillator, often called a LifeVest, may be considered as temporary protection for selected high-risk patients while the heart recovers. It is not routinely prescribed to everyone after a heart attack because evidence of a survival benefit for all patients is mixed. If prescribed, it generally needs to be worn nearly continuously except when bathing.
What medicines are optimized before deciding about an ICD?
Doctors commonly optimize beta-blockers; ACE inhibitors, ARBs, or ARNIs; mineralocorticoid-receptor antagonists; and SGLT2 inhibitors. Doses are adjusted based on blood pressure, heart rate, kidney function, and potassium levels. Antiplatelet medicines and statins may also be used to reduce the chance of another heart attack.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on acute myocardial infarction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my exact ejection fraction, and when is my next echocardiogram scheduled to recheck it?
  2. 2.Are my heart failure medications at the highest doses my blood pressure and kidneys can safely tolerate?
  3. 3.Based on my specific risk factors and rhythm history, am I a candidate for a wearable cardioverter-defibrillator (WCD) while we wait?
  4. 4.Have any of my monitors shown abnormal rhythms like non-sustained ventricular tachycardia (NSVT)?
  5. 5.If my ejection fraction remains low, will I need an electrophysiology consultation or a specialized device like a CRT-D?

References

References (21)
  1. 1

    Wearable Cardioverter-Defibrillator after Myocardial Infarction.

    Olgin JE, Pletcher MJ, Vittinghoff E, et al.

    The New England journal of medicine 2018; (379(13)):1205-1215 doi:10.1056/NEJMoa1800781.

    PMID: 30280654
  2. 2

    The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape.

    Wong JA, Roberts JD, Healey JS

    The Canadian journal of cardiology 2021; (37(4)):644-654 doi:10.1016/j.cjca.2021.01.024.

    PMID: 33549824
  3. 3

    Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.

    Malgie J, Clephas PRD, Brunner-La Rocca HP, et al.

    Heart failure reviews 2023; (28(5)):1221-1234 doi:10.1007/s10741-023-10325-2.

    PMID: 37311917
  4. 4

    Optimal Timing of Cardioverter-Defibrillator Implantation in Patients with Left Ventricular Dysfunction after Acute Myocardial Infarction.

    Ursaru AM, Costache II, Petris AO, et al.

    Reviews in cardiovascular medicine 2022; (23(4)):124 doi:10.31083/j.rcm2304124.

    PMID: 39076214
  5. 5

    Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?

    Abdelhamid M, Rosano G, Metra M, et al.

    European journal of heart failure 2022; (24(9)):1460-1466 doi:10.1002/ejhf.2594.

    PMID: 35753058
  6. 6

    Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.

    Mueller-Leisse J, Brunn J, Zormpas C, et al.

    Sensors (Basel, Switzerland) 2022; (22(5)) doi:10.3390/s22052037.

    PMID: 35271182
  7. 7

    Heart failure as a substrate and trigger for ventricular tachycardia.

    Alvarez CK, Cronin E, Baker WL, Kluger J

    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2019; (56(3)):229-247 doi:10.1007/s10840-019-00623-x.

    PMID: 31598875
  8. 8

    Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.

    Vaduganathan M, Claggett BL, Jhund PS, et al.

    Lancet (London, England) 2020; (396(10244)):121-128 doi:10.1016/S0140-6736(20)30748-0.

    PMID: 32446323
  9. 9

    Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?

    Hu JR, Schwann AN, Tan JW, et al.

    Heart failure clinics 2024; (20(4)):373-386 doi:10.1016/j.hfc.2024.06.004.

    PMID: 39216923
  10. 10

    Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.

    Tomasoni D, Pagnesi M, Colombo G, et al.

    European journal of heart failure 2024; (26(2)):327-337 doi:10.1002/ejhf.3081.

    PMID: 37933210
  11. 11

    The independent reduction in mortality associated with guideline-directed medical therapy in patients with coronary artery disease and heart failure with reduced ejection fraction.

    Wolfe NK, Mitchell JD, Brown DL

    European heart journal. Quality of care & clinical outcomes 2021; (7(4)):416-421 doi:10.1093/ehjqcco/qcaa032.

    PMID: 32324852
  12. 12

    [Updated ESC guideline: innovations for the treatment of ventricular arrhythmias and recommendations for prevention of sudden cardiac death].

    Eckardt L, Deneke T

    Herzschrittmachertherapie & Elektrophysiologie 2016; (27(3)):288-94 doi:10.1007/s00399-016-0446-2.

    PMID: 27581243
  13. 13

    New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.

    Karacan MN, Doi SN, Yafasova A, et al.

    European journal of heart failure 2024; (26(6)):1423-1431 doi:10.1002/ejhf.3239.

    PMID: 38733253
  14. 14

    Current Device Therapies for Sudden Cardiac Death Prevention - the ICD, Subcutaneous ICD and Wearable ICD.

    Chieng D, Paul V, Denman R

    Heart, lung & circulation 2019; (28(1)):65-75 doi:10.1016/j.hlc.2018.09.011.

    PMID: 30389367
  15. 15

    Implantable cardioverter-defibrillator implantation for primary and secondary prevention: indications and outcomes.

    Pick JM, Batra AS

    Cardiology in the young 2017; (27(S1)):S126-S131 doi:10.1017/S1047951116002365.

    PMID: 28084973
  16. 16

    Recurrent ventricular arrhythmias and mortality in cardiac arrest survivors with a reversible cause with and without an implantable cardioverter defibrillator: A systematic review.

    van der Lingen ACJ, Woudstra J, Becker MAJ, et al.

    Resuscitation 2022; (173()):76-90 doi:10.1016/j.resuscitation.2022.02.019.

    PMID: 35227821
  17. 17

    Baroreflex sensitivity assessed with the sequence method is associated with ventricular arrhythmias in patients implanted with a defibrillator for the primary prevention of sudden cardiac death.

    Garcia R, Degand B, Fraty M, et al.

    Archives of cardiovascular diseases 2019; (112(4)):270-277 doi:10.1016/j.acvd.2018.11.009.

    PMID: 30670362
  18. 18

    Use of the Wearable Cardioverter Defibrillator in High-Risk Populations.

    Lamichhane M, Safadi A, Surapaneni P, et al.

    Current cardiology reports 2016; (18(8)):78 doi:10.1007/s11886-016-0746-5.

    PMID: 27319008
  19. 19

    The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?

    Barsheshet A, Vamvouris T, Goldenberg I

    Expert review of medical devices 2016; (13(7)):627-32 doi:10.1080/17434440.2016.1200969.

    PMID: 27333818
  20. 20

    Wearable Cardioverter-Defibrillator in Patients at Transient Risk of Sudden Cardiac Death: State of the Art and Contemporary Clinical Evidence.

    Matteucci A, Bonanni M, Mariani MV, et al.

    Diagnostics (Basel, Switzerland) 2026; (16(18)) doi:10.3390/diagnostics16182990.

    PMID: 42793775
  21. 21

    Ventricular tachycardia-inducibility predicts arrhythmic events in post-myocardial infarction patients with low ejection fraction. A systematic review and meta-analysis.

    Disertori M, Masè M, Rigoni M, et al.

    International journal of cardiology. Heart & vasculature 2018; (20()):7-13 doi:10.1016/j.ijcha.2018.06.002.

    PMID: 29942854

This page provides general information about ICD timing after a heart attack with low ejection fraction and is not medical advice. Your cardiologist or electrophysiologist can assess your recovery, rhythm history, and device options.